EHA Unplugged

Join Prof Paolo Ghia and our host Dr Enrica Orsini as they discuss the treatment of Chronic Lymphocytic Leukemia (CLL) from the perspectives of patients and doctors.In this episode, they discuss the factors that influence the decision of treatment choices from the perspectives of patients and doctors and how both parties have different perspectives on the subject. They further highlight the importance of understanding the differing priorities between these two groups and the need for shared decision-making in the treatment process.The podcast is based on the paper: "What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment", by Laurenti L et al., published on HemaSphere in 2022.Host: Dr Enrica Orsini; Guest: Prof Paolo GhiaLearn MoreTo learn more about CLL and updated treatment recommendations, check out our comprehensive CLL Program on the EHA Campus.Discover more of EHA's social media microlearning here.What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe

Treatment of low-risk patients with polycythemia vera (PV) and myelofibrosis (MF) is still a matter of debate. Although traditionally these patients were managed exclusively with supportive treatment, more recent guidelines suggest the opportunity of identifying subgroups of patients eligible for cytoreduction. In this debate recorded during the EHA22 Annual Congress, experts Claire Harrison and Christen Lykkegaard Andersen support opposite statements on this topic, discussing the pros and cons of cytoreductive treatment in low-risk PV and MF patients, with the aid of representative clinical cases.Learn MoreIf you liked this podcast and would like to explore related content, you can check out our Polycythemia Vera course on the EHA Campus.What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe

Join our guest Dr Martin Kaiser and host Dr Nathalie van Havre, as they talk about Heath Technology Assessment (HTA) in hematology and in Europe’s public healthcare landscape.Our speakers discuss the relevance of HTA for hematologists and how it aims to standardize access to new health technologies for patients across Europe. Furthermore, they examine the challenges in generating solid evidence to support these assessments, particularly in the case of rare diseases, and whether HTAs are likely to cause new delays for new health technologies to reach the patients.Next, the social and economic implications of HTA are discussed, in particular costs, limited resources, and equality in access to treatment. Dr Kaiser concludes this podcast by emphasizing the importance of HTA education and awareness in medical education. Host: Dr Nathalie van Havre; Guest: Dr Martin KaiserLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe

In this podcast, you will listen to Prof Antonis Kattamis summarizing the last developments in the treatment of patients with thalassemia. While the life expectancy of these patients has considerably improved in the last decades, quality of life and disease burden is still a relevant issue. However, new classes of drugs, with action of the pathophysiologic mechanisms of the disease, are entering the clinics—drugs able to improve globin chain imbalance or ineffective erythropoiesis, or decrease hemolysis. Prof Kattamis will discuss the efficacy of these treatments and of innovative gene therapy approaches, not neglecting economic evaluations on the sustainability of new treatments in thalassemia.Guest: Prof Antonis KattamisThis podcast was recorded as a Spotlight Talks session during EHA2022. More podcasts from EHA2022 will be available in the future. Stay tuned!View this podcast on EHA Campus for key slides related to this episode.Learn MoreIf you liked this podcast and would like to explore related content, you can check out our EHA Thalassemia Program on the EHA Campus.For more social media microlearning from EHA, visit https://ehaedu.org/SM_Learning. What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive EHA Educational Updates via https://eha.news/subscribe

In this podcast, Prof Paolo Ghia discusses the current treatment landscape of Chronic Lymphocytic Leukemia (CLL), providing a guide for clinicians faced with an ever-growing number of therapeutic alternatives. Within targeted therapies, a special focus is dedicated to BTK inhibitors and their different characteristics, and to the long-term results of the ASCEND trial. The management of CLL is changing rapidly, and Prof Ghia's expertise can help hematologists to choose the right treatment for their patients, even in high-risk cases, such as the ones with TP53 mutation or del(17p).The podcast is based on the paper: "Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results", by Ghia P et al., published on HemaSphere in 2022.Host: Dr Enrica Orsini; Guest: Prof Paolo GhiaLearn MoreTo learn more about CLL and updated treatment recommendations, check out our comprehensive CLL Program on the EHA Campus.Discover more of EHA's social media microlearning here.What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe

In this podcast, Prof Mario Cazzola illustrates the genesis of the new ICC classification of myeloid neoplasms, published in 2022 (Arber DA et al, Blood 2022), with a special focus on MDS, and the new nosological entities that have been defined in it.The new entities, namely SF3B1-mutant MDS, TP53 multi-hit MDS, and clonal cytopenia of undetermined significance (CCUS), underline the importance of gene sequencing for the diagnosis and risk stratification of myeloid neoplasms and MDS in particular.Guest: Prof Mario CazzolaThis podcast was recorded as a Spotlight Talks session during EHA2022. More podcasts from EHA2022 will be available in the future. Stay tuned!View this podcast on EHA Campus for key slides related to this episode.Learn MoreIf you liked this podcast and would like to explore related content, you can check out our MDS Flashcards on the EHA Campus.What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe

What are the latest guidelines for the management of patients with Transfusion-Dependent Thalassemia (TDT)?In 2022, the fourth edition of the TIF (Thalassemia International Federation) guidelines for the management of patients with transfusion-dependent thalassemia (TDT) was published. In this podcast, Prof Ali Taher discusses with our host, Dr Nathalie van Havre, the main news of this edition, including genetic work-up, chelation therapy, and prevention and management of complications.Furthermore, Prof Taher illustrates the innovative gene therapy approaches and new drugs (such as luspatercept, the most recently approved drug for TDT) currently available for the treatment of these patients and how they can impact the management of TDT.The podcast is based on the paper "2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia", by Farmakis D et al., published in HemaSphere in 2022 (HemaSphere. 2022;6:e732).Host: Dr Nathalie van Havre; Guest: Prof Ali TaherThis is the sixth of a series of podcasts discussing recently published scientific articles. More podcasts will be available in the future. Stay tuned!Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe

Spotlight Talks: Updates on the Classification of Hematolymphoid Neoplasms: Lymphoid DiseasesIn this podcast, Prof John Gribben, former President of EHA, discusses the new ICC lymphoid malignancies classification (Campo E, et al. Blood, 2022), highlighting the main novelties introduced for specific entities and explaining the new criteria guiding the diagnosis and prognosis of lymphoproliferative diseases. Listen to this podcast to gain an overview of the most innovative findings in the field, while waiting for the updated WHO classification to be published in 2023.Guest: Prof John GribbenThis podcast was recorded as a Spotlight Talks session during EHA2022. More podcasts from EHA2022 will be available in the future. Stay tuned!What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe

Is CAR-T economically sustainable?Join our guest Prof Martin Dreyling and host Dr Nathalie van Havre as they discuss the costs of CAR-T cell therapy for the treatment of blood disorders at an individual level and whether it is economically sustainable for health systems.Listen along as they consider the financial challenges of patient selection for this costly life-saving therapy, based on Prof Dreyling’s experience with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) patients. Challenges touched upon include reimbursement policies, time lags and associated costs of personalized therapy, and choosing the indications to include.Prof Dreyling further offers his insights into the overall financial burden for health systems based on his participation on a recent Budget Impact Analysis (BIA) carried out in DLBCL patients in Germany. Finally, our guests contemplate cancer immunotherapy perspectives for the coming years, including bispecific antibodies as a potentially cost-effective alternative in development.The details of the BIA were recently described in the article Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany published in HemaSphere by Skalt D, Moertl B, von Bergwelt-Baildon M, Schmidt C, Schoel W, Bücklein V, Weiglein T, Dreyling M, and Berger K.Host: Dr Nathalie van Havre; Guest: Prof Martin DreylingThis is the fifth of a series of podcasts discussing recently published scientific articles. More podcasts will be available in the future. Stay tuned!Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe

What is Plan S and what has happened to it?Join our guest Dr Nuno Borges and host Dr Christian Scharenberg as they talk about the core principles, goals, and challenges of Plan S.Listen along as Dr Borges discusses the controversies aroused by Plan S and the “publish or perish” paradigm faced by early career scientists. Dr Borges ends this podcast on a positive note where he believes that slowly, but surely, and thanks to social media, we are heading towards a future where scientific publications will be open access and freely available to everyone.This discussion is based on the recently published article Change is Coming: Plan S From the Early Career Scientist Perspective in HemaSphere by Dr Nuno Borges.Host: Dr Christian Scharenberg; Guest: Dr Nuno BorgesThis is the fourth of a series of podcasts discussing recently published scientific articles. More podcasts will be available in the future. Stay tuned!Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe

What is clonal hematopoiesis of indeterminate potential (CHIP) and its associated risks in elderly patients?Join our guest Prof Kirsten Gronbaek and host Dr Christian Scharenberg as they discuss CHIP, its biological significance, frequency in the general population, and its association with epigenetic age. Listen along as Prof Gronbaek dives deeper into the subject and explains the association and significance of CHIP with mutations and patient survival. Last but not least, Prof Gronbaek talks about the challenges and current landscape of trials and studies on treatment for CHIP.This discussion is based on the recently published article Clonal Hematopoiesis and Epigenetic Age Acceleration in Elderly Danish Twins in HemaSphere.Host: Dr Christian Scharenberg; Guest: Professor Kirsten GronbaekThis is the third of a series of podcasts discussing recently published scientific articles. More podcasts will be available in the future. Stay tuned!  Learn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe

What can a not-for-profit NGO do for patients in a time of war? Join our guests, Prof Konstanze Döhner, Prof Elizabeth Macintyre, and Dr Nathalie van Havre as they discuss what the European Hematology Association (EHA) has done in favor of Ukraine and the Ukrainian hematological community. Our guests talk about support programs EHA has implemented and the obstacles that came with that. Prof Macintyre furthers the discussion by expressing her views on the role of medical organizations such as EHA in a crisis. This discussion is based on the recently published article How a Medical Association Can Make a Difference in a Crisis Situation in HemaSphere by Dr Nathalie van Havre.This is the second of a series of podcasts discussing recently published scientific articles, more podcasts will be available in the future. Stay tuned!Guests: Prof Konstanze Döhner, University Hospital of Ulm, Germany; Prof Elizabeth Macintyre, Hôpital Necker-Enfants Malades et Université Paris Cité, France;Dr Nathalie van Havre, EHA Executive Office, The NetherlandsLearn MoreWhat did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe

Join our guest Prof David Rees and host Dr Christian Scharenberg as they discuss how the concept of precision medicine can be applied to Sickle Cell Disease (SCD).Listen as Prof David Rees talks about prognostic markers and how they can (or can't) guide SCD disease management, current and new treatment options for SCD patients, and how the situation of precision medicine can differ between low- and high-income countries. Last but not least, Prof David Rees ends the podcast with his view of how SCD management will be in the near and far future.This discussion is based on a recently published article, Precision Medicine and Sickle Cell Disease by Prof David Rees, in Hemasphere. This is the first of a series of podcasts discussing recently published articles. More podcasts in this series will be available in the future. Stay tuned!Visit the EHA Campus for more content on Hemoglobinopathies and Sickle Cell Disease: 1. EHA Sickle cell disease program 2. EHA Unplugged Sickle Cell Disease podcast series (Available on all major podcast platforms and on the EHA Campus)3. Gene Therapy in HemoglobinopathiesHost: Dr Christian Scharenberg, Skaraborgs Hospital, Sweden; Guest: Professor David Rees, Kings College London, United KingdomWhat did you think of this podcast? Share your opinion with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe

How did CLL lose its role of "Cinderella" in hematology in the last decades, thanks to the introduction of entirely new classes of drugs, and came under the spotlight of clinical research in hematology? Prof Jennifer Woyach discusses the fundamentals of CLL genetics and treatment in this podcast, as well as the selection of patients for therapy, the different, and somewhat unpredictable, clinical course the disease can follow, together with the last evidence from CLL clinical trials. Host: Prof Shaun McCann; Guest: Prof Jennifer WoyachWhat did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe

The links between thrombosis and cancer have been known for a long time and are associated with the type of cancer (pancreatic and lung carcinomas, for example, are particularly prone to give this complication), its localization, and the anti-neoplastic treatment used to fight the cancer itself. Prof Jan Marie Connors, in this podcast, explains how a thrombotic episode may represent the first indication of a cancer diagnosis, and how guidelines should be critically used to manage these patients, taking into account the concurrent anti-cancer therapy and potential drug interactions. Host: Prof Shaun McCann; Guest: Prof Jean Marie ConnorsWhat did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe

In this podcast, Prof Tessa Andermann, an expert in infectious diseases, provides an overview of the role of the microbiome in the homeostasis of the human body and how it has been implicated in the development of complications after allogeneic transplantations, including acute graft-versus-host-disease, infections, mortality, and disease relapse. Some of the relationships observed between changes in the microbiome and clinical outcome might in the next future be better characterized and exploited to drive therapeutic choices. Host: Prof Shaun McCann; Guest: Prof Tessa Andermann What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe

How do you make a diagnosis of erythrocytosis? Is full blood count enough or do you need more specific tests? How is the classification in primary and secondary erythrocytosis linked to EPO levels? Is idiopathic erythrocytosis really a vanishing entity? These are some of the questions Prof Mary-Frances McCullin answers in this podcast, giving listeners the key information necessary to understand erythrocytosis in clinical practice.Host: Prof Shaun McCann; Guest: Prof Mary-Frances McMullinWhat did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe

In the seventh and final episode of the Clinical Trial podcast series, you can hear Prof. Konstanze Döhner and Prof. Antonio Almeida exchanging ideas and thought-provoking opinions about how investigator-initiated clinical trials and new trial designs can provide patients early access to novel drugs.They discuss the importance of large collaborative groups, the complexity of current requirements that must be in place, and the impact that these challenges may have, along with the relevant issues that could be changed in order to enable more uncomplicated participation and conduction of clinical studies.In this series of Clinical Trial podcasts produced by EHA, experts unravel for you the many issues linked to the design and execution of a clinical study, complementing the information present in our Clinical Trial Map.It will help you answer interrogations such as:• What is a CRO?• How are clinical studies designed?• Which role(s) should sponsors fulfil?Experts will talk directly to you to give you an overview of several essential clinical research topics in a series of 6 podcasts.Host: Prof. Konstanze Döhner; Prof. Antonio AlmeidaWhat did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more podcasts or check out the Clinical Trial Map? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe

This series of two podcasts leads you on a journey through the main clinical and therapeutical aspects of Cutaneous T Cell Lymphomas (CTCLs), a heterogeneous group of lymphoid neoplasms characterized by primary cutaneous localization. Albeit rare, CTCLs have peculiar clinical characteristics, requiring a multidisciplinary approach and a strict collaboration between different specialists, allowing for a timely and precise diagnosis, critical for the good outcome of these patients.Join dermatologist Prof Maarten Vermeer (Dept. of Dermatology, Leiden University Medical Center) and hematologist Dr Erik Marijt (Head of the Central Laboratory of Clinical Hematology and the Interdivisional Flowcytometry Core Facility, Leiden University Medical Center) as they exchange their views and expertise on the diagnosis and management of patients with CTCLs.In this second episode, listen to Prof Vermeer and Dr Marijt discussing how CTCL patients with localized and diffuse disease can be effectively treated, and how new targeted agents and allogeneic transplantation can be integrated into the management algorithm.Hosts: Prof Maarten Vermeer; Dr Erik MarijtWhat did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe

This series of two podcasts leads you on a journey through the main clinical and therapeutical aspects of Cutaneous T Cell Lymphomas (CTCLs), a heterogeneous group of lymphoid neoplasms characterized by primary cutaneous localization. Albeit rare, CTCLs have peculiar clinical characteristics, requiring a multidisciplinary approach and a strict collaboration between different specialists, allowing for a timely and precise diagnosis, critical for the good outcome of these patients.Join dermatologist Prof Maarten Vermeer (Dept. of Dermatology, Leiden University Medical Center) and hematologist Dr Erik Marijt (Head of the Central Laboratory of Clinical Hematology and the Interdivisional Flowcytometry Core Facility, Leiden University Medical Center) as they exchange their views and expertise on the diagnosis and management of patients with CTCLs.In this first episode, listen to Prof Vermeer and Dr Marijt illustrating the dermatologic and hematologic approaches to the diagnosis and staging of CTCLs, including the different clinical presentation and prognosis of the most common types of CTCLs.Hosts: Prof Maarten Vermeer; Dr Erik MarijtWhat did you think of this podcast? Share your opinions with us in this short feedback survey.Provide FeedbackWould you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/CampusSubscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe